November 15, 2013 — Guerbet announced that Novation, a health care supply chain expertise, analytics and contracting company, awarded an agreement for Dotarem (gadoterate meglumine) Injection, a gadolinium-based contrast agent (GBCA) indicated for intravenous use with magnetic resonance imaging (MRI) in intracranial, spine and associated tissues in adult and pediatric patients (ages two and older) to detect and visualize areas with disruption of the blood brain barrier and/or abnormal vascularity.
Novation awarded the agreement through its Innovative Technology program, which seeks to identify and contract for innovative products that are used in clinical care and offer an incremental benefit to the care and safety of a patient and health care worker. The agreement became effective Nov. 1.
For more information: www.guerbet.com
March 31, 2026 
